Ask HopeStage to review this study with me
Study ID: NCT02700685. We help you review the study, but cannot decide medical eligibility.
CompletedNCT02700685
Effect of Pycnogenol® on ADHD
This study is completed. It focuses on ADHD and currently lists study information in Belgium.
ADHDOtherFrom 6 Years to 12 Years
Key information made simple
What is this study testing?
This study is testing whether the study approach may be useful for children experiencing ADHD.
What would participation involve?
Participants may complete study activities around the study approach, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in Belgium.
Who is it mainly for?
This study appears to be mainly for children with ADHD. Because it involves minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about whether there is a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
The official record suggests in-person participation through a hospital, with sites including Universitaire Kinder- en Jeugdpsychiatrie in Borgerhout, University Hospital Antwerp in Edegem, and University Hospital Ghent. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually being able to understand the study and consent and meeting the main study requirements, while common reasons not to take part include safety concerns that need urgent care first and other factors that could make participation unsuitable. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: September 1, 2017
- Recruitment status
- Completed
- Estimated enrollment
- Not clearly listed
- Sponsor
- Nina Hermans
- Sponsor type
- Unknown or unclear
- Study type
- Other
- Intervention type
- Other / unclear
- Study phase
- Not clearly listed
- Locations
- Belgium
- Age range
- From 6 Years to 12 Years
- Official registry ID
- NCT02700685
- Official title
- Effect of Pycnogenol® on ADHD
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT02700685. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Belgium.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring observational follow-up for people with adhd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Why is the study type not clearly categorized?
The study type is not clearly categorized in the public registry. Focus on the objective, required tasks, visits, any intervention, and eligibility criteria, then ask the study team to confirm.
Who might this study be for?
This study may concern people with adhd; age range: From 6 Years to 12 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
The public registry does not clearly describe all participation steps. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What risks or points should I check?
The public registry does not make the main risk category clear. Ask the study team what activities are required, what could feel uncomfortable, how safety is monitored, and what happens if you want to stop. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Nina Hermans, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is completed. It may still be useful for understanding the research, but you are unlikely to be able to join.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT00700427
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This study is completed. It focuses on ADHD and currently lists study information in Austria, Belgium, Finland, France, Germany, Italy, the Netherlands, Portugal, Spain, Sweden, Switzerland, and the United Kingdom.
CompletedNCT04085172
TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)
This study is completed in the United States, in the United Kingdom, in Belgium, .... It is testing TAK-503 for ADHD.
CompletedNCT00714688
Effectiveness of Effectiveness and Safety of Prolonged Release OROS Methylphenidate in ADHD
This study is completed in France, in the United Kingdom, in Switzerland, .... It is testing Effectiveness and Safety of Prolonged Release OROS Methylphenidate for ADHD.